Mein Warenkorb

Angiopoietin-like 3

Angiopoietin-like 3 Molekülinformation

Englischer NameAngiopoietin like 3Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel14Target-AliasAngiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameAngiopoietin like 3
Target-AliasAngiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel14
Höchste Forschungs- und EntwicklungsphaseApproved

Angiopoietin-like 3 Produktliste

  • Attribut

    Protein (5)

  • Produktbibliothek

    Online (5)

  • Spezies

    Human (4)Mouse (1)

  • Etikett

    His Tag (3)His Tag & Avi Tag (1)Fc Tag (1)

  • Marker

    Unconjugated (4)Biotin-labeled (1)

Angiopoietin-like 3 Molekülhintergrund

Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Angiopoietin-like 3 Molekülalias

ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
ZodasiranARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals)Phase 3 ClinicalRoche LtdDyslipidemias; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia
Details
LNA-043LNA-043Phase 2 ClinicalNovartis Pharma AgKnee Injuries; Osteoarthritis; Osteoarthritis, Knee
Details
VupanorsenISIS-703802; PF-07285557Phase 2 ClinicalIonis Pharmaceuticals IncCardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Homozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
EDP-167EDP-167; EDP167Phase 2 ClinicalEteng Pharmaceutical (Zhuhai) Co LtdDyslipidemias; Homozygous familial hypercholesterolemia
Details
ALN-ANG3ALN-ANG3Phase 2 ClinicalAlnylam Pharmaceuticals IncDiabetic Nephropathies
Details
BW-00112BW-00112; BW00112Phase 2 ClinicalShanghai Argo Biopharmaceutical Co LtdDyslipidemias; Hypertriglyceridemia
Details
SolbinsiranLY-3561774; DCR-CM-1; DCR-CM1Phase 2 ClinicalDicerna Pharmaceuticals IncCardiovascular Diseases; Dyslipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases
Details
JS-401JS-401; RP-912Phase 1 ClinicalRisen (Suzhou) Pharma Tech Co LtdHyperlipidemias; Metabolic Diseases
Details
VERVE-201VERVE-201Phase 1 ClinicalBroad Institute, Harvard UniversityAtherosclerosis; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia
Details
SYH-2070SYH2070; SYH-2070Phase 1 ClinicalCspc Heibei Zhongrun Pharmaceutiacl Co LtdHyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia
Details
NN-6491NN6491; NN-6491Phase 1 ClinicalNovo Nordisk A/SCardiovascular Diseases
Details
NNC0491-6075NNC0491-6075; NNC04916075Phase 1 ClinicalNovo Nordisk A/SDyslipidemias
Details
AZD-1705AZD1705; AZD-1705Phase 1 ClinicalAstrazeneca Plc, Parexel International CorpCardiovascular Diseases
Details
CTX-310CTX-310; CTX310Phase 1 ClinicalCrispr Therapeutics AgCardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases; Sitosterolemia
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
EvinacumabREGN-1500ApprovedRegeneron Pharmaceuticals IncEvkeezaUnited StatesHypercholesterolemia; Homozygous familial hypercholesterolemiaRegeneron Pharmaceuticals Inc2021-02-11Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Metabolic Diseases
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns